A clinical trial for Novo Nordisk Pharma's obesity drug, 'Wegovy (semaglutide),' will be conducted in South Korea for expanded indication.

On September 20th, the Ministry of Food and Drug Safety (MFDS) has approved the 'Phase 2 clinical trial to evaluate the efficacy, safety, and dosage testing of NNC0519-0130, subcutaneously administered once-weekly, in comparison to Ozempic (semagluide) 1.0 mg and placebo in overweight or obese patients who have or do not have type 2 diabetes.'

The clinical trial will involve 456 individuals worldwide from December 2024 to September 2026. In South Korea, the study will enroll 32 patients and will be conducted at Pusan National University Hospital, Ils